Cerliponase alfa Disease Interactions
There are 2 disease interactions with cerliponase alfa.
Cerliponase alfa (applies to cerliponase alfa) hydrocephalus
Major Potential Hazard, Moderate plausibility. Applicable conditions: CNS Disorder
The use of cerliponase alfa is contraindicated in patients with ventriculoperitoneal shunts and those patients with acute intraventricular access device-related complications such as leakage, device failure, or device-related infection.
References
- (2017) "Product Information. Brineura (cerliponase alfa)." BioMarin Pharmaceutical Inc
Cerliponase alfa (applies to cerliponase alfa) arrhythmias
Moderate Potential Hazard, Moderate plausibility.
The use of cerliponase alfa may cause cardiovascular complications. It is recommended to monitor vital signs (blood pressure, heart rate) before infusion starts, periodically during infusion, and post-infusion. Perform electrocardiogram (ECG) monitoring during infusion in patients with a history of conduction abnormalities. In patients without cardiac abnormalities, regular 12-lead ECG evaluations should be performed every 6 months.
References
- (2017) "Product Information. Brineura (cerliponase alfa)." BioMarin Pharmaceutical Inc
More about cerliponase alfa
- cerliponase alfa consumer information
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: lysosomal enzymes
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.